Neuroscience News and Research

RSS

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Elan Corporation, plc announced today that Elan's wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., commenced an offer to purchase of up to $186,000,000 aggregate principal amount of their 8 7/8% Senior Fixed Rate Notes due 2013 (the "2013 Fixed Rate Notes") and their Floating Rate Notes Due 2013 (the "2013 Floating Rate Notes" together with the 2013 Fixed Rate Notes, the "2013 Notes"),

31 Aug 2010

St. Mary's Medical Center to implement ProVation Order Sets customizable authoring and management solution

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that St. Mary's Medical Center has selected ProVation® Order Sets, powered by UpToDate® Decision Support, as the organization's electronic order set solution.

30 Aug 2010

Smoked cannabis relieves chronic neuropathic pain

The medicinal use of cannabis has been debated by clinicians, researchers, legislators and the public at large for many years as an alternative to standard pharmaceutical treatments for pain, which may not always be effective and may have unwanted side effects. A new study by McGill University Health Centre (MUHC) and McGill University researchers provides evidence that cannabis may offer relief to patients suffering from chronic neuropathic pain.

30 Aug 2010

Eisai receives new action date for FDA priority review of eribulin mesylate NDA for metastatic breast cancer

Eisai Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date of September 30, 2010.

30 Aug 2010

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

23rd ECNP Press conference on impact of circadian rhythms on human brain

All humans are synchronised to the rhythmic light-dark changes that occur on a daily basis. Rhythms in physiological and biochemical processes and behavioural patterns persist in the absence of all external 24-hour signals from the physical environment, with a period that is close to 24 hours

30 Aug 2010

23rd ECNP Congress press conference

The incidence of psychotic disorders varies greatly across places and demographic groups, as do symptoms, course, and treatment response across individuals. High rates of schizophrenia in large cities, and among immigrants, cannabis users, and traumatised individuals reflect the causal influence of environmental exposures. This, in combination with progress in the area of molecular genetics, has generated interest in more complicated models of schizophrenia aetiology that explicitly posit gene-environment interactions.

30 Aug 2010

Researchers examine functions of neuronal diversity

Much like snowflakes, no two neurons are exactly alike. But it's not the size or shape that sets one neuron apart from another, it's the way it responds to incoming stimuli. Carnegie Mellon University researchers have discovered that this diversity is critical to overall brain function and essential in how neurons process complex stimuli and code information.

30 Aug 2010

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel.

30 Aug 2010

'Neural inertia' may explain brain's resistance to changes in consciousness

Despite the fact that an estimated 25 million patients per year in the U.S. undergo surgeries using general anesthesia, scientists have only been able to hypothesize exactly how anesthetics interact with the central nervous system. They previously thought that the processes of "going under" and waking up from anesthesia affected the brain in the same way.

27 Aug 2010

Increase in regeneration of nerve cells can alleviate or prevent memory loss

Production of new nerve cells in the human brain is linked to learning and memory, according to a new study from the University of Florida. The research is the first to show such a link in humans. The findings, published online and in an upcoming print issue of the journal Brain, provide clues about processes involved in age- and health-related memory loss and reveal potential cellular targets for drug therapy.

27 Aug 2010

Study finds moderate exercise enhances DMN connectivity in specific regions of brain

A group of "professional couch potatoes," as one researcher described them, has proven that even moderate exercise - in this case walking at one's own pace for 40 minutes three times a week - can enhance the connectivity of important brain circuits, combat declines in brain function associated with aging and increase performance on cognitive tasks.

27 Aug 2010

Auditory neurons accept first sound, ignore subsequent reverberations: Study

Voices carry, reflect off objects and create echoes. Most people rarely hear the echoes; instead they only process the first sound received. For the hard of hearing, though, being in an acoustically challenging room can be a problem. For them, echoes carry.

27 Aug 2010

AgeneBio receives grant to develop neural stabilizer therapy for amnestic mild cognitive impairment

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.

27 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Research on myosin II protein can lead to novel treatment for memory disorders

Scientists from the Florida campus of The Scripps Research Institute have discovered a mechanism that plays a critical role in the formation of long-term memory. The findings shed substantial new light on aspects of how memory is formed, and could lead to novel treatments for memory disorders.

26 Aug 2010

Motor proteins play critical role in stabilization of long-term memories

Functioning much like gears in a machine, cellular motor proteins are critical to dynamic functions throughout the body, including muscle contraction, cell migration and cellular growth processes. Now, neuroscientists from UC Irvine and the Florida campus of The Scripps Research Institute report that motor proteins also play a critical role in the stabilization of long-term memories. The findings add an unexpected dimension to the story of how memories are encoded and suggest new targets for therapeutic interventions.

26 Aug 2010

Saint Thomas Health Services to offer program for neurosurgical patients’ better care

August is Neurosurgery Outreach Month, an effort to increase the public's knowledge about the powerful effects of neurosurgery, many of which are taking place at Saint Thomas Health Services in Tennessee.

26 Aug 2010

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

People with insulin resistance and type 2 diabetes appear to be at an increased risk of developing plaques in the brain that are associated with Alzheimer's disease, according to new research published in the August 25, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

26 Aug 2010

Neuroscience News and Research

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

St. Mary's Medical Center to implement ProVation Order Sets customizable authoring and management solution

Smoked cannabis relieves chronic neuropathic pain

Eisai receives new action date for FDA priority review of eribulin mesylate NDA for metastatic breast cancer

Latest achievements in brain research and treatment for mental disorders

23rd ECNP Press conference on impact of circadian rhythms on human brain

23rd ECNP Congress press conference

Researchers examine functions of neuronal diversity

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

'Neural inertia' may explain brain's resistance to changes in consciousness

Increase in regeneration of nerve cells can alleviate or prevent memory loss

Study finds moderate exercise enhances DMN connectivity in specific regions of brain

Auditory neurons accept first sound, ignore subsequent reverberations: Study

AgeneBio receives grant to develop neural stabilizer therapy for amnestic mild cognitive impairment

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Research on myosin II protein can lead to novel treatment for memory disorders

Motor proteins play critical role in stabilization of long-term memories

Saint Thomas Health Services to offer program for neurosurgical patients’ better care

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Type 2 diabetes, insulin resistance increases risk for Alzheimer's disease: Research

Event guide: 2nd Neuroscience Innovation Partnering & Licensing Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News